Amin Jahanbakhshi

Dr. Amin Jahanbakhshi

Neurosurgery Department, Iran University of Medical Sciences, Tehran, Iran.
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2015 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
MJMaryam Jalessi
Maryam Jalessi
AJAmin Jahanbakhshi
Amin Jahanbakhshi
EAElahe Amini
Elahe Amini
SKSeyyed Kamran Kamrava
Seyyed Kamran Kamrava
MFMohammad Farhadi
Mohammad Farhadi

4 February 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
SCSalvatore Cozzi
Salvatore Cozzi
MNMasoumeh Najafi
Masoumeh Najafi
MGMarzieh Gomar
Marzieh Gomar
PCPatrizia Ciammella
Patrizia Ciammella
CICinzia Iotti
Cinzia Iotti
AJAmin Jahanbakhshi
Amin Jahanbakhshi
Background: Dendritic cell vaccination (DCV) strategies, thanks to a complex immune response, may flare tumor regression and improve patients’ long-term survival. This meta-analysis aims to assess the efficacy of DCV for newly diagnosed glioblastoma patients in clinical trials. Methods: The study databases, including PubMed, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were searched by two blinded investigators considering eligible studies based on the following keywords: “glioblastoma multiforme”, “dendritic cell”, “vaccination”, “immunotherapy”, “immune system”, “immune response”, “chemotherapy”, “recurrence”, and “temozolomide”. Among the 157 screened, only 15 articles were eligible for the final analysis. Results: Regimens including DCV showed no effect on 6-month progression-free survival (PFS, HR = 1.385, 95% CI: 0.822–2.335, p = 0.673) or on 6-month overall survival (OS, HR = 1.408, 95% CI: 0.882–2.248, p = 0.754). In contrast, DCV led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid-term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in patients affected by a very poor prognosis.

22 April 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MNMasoumeh Najafi
Masoumeh Najafi
AJAmin Jahanbakhshi
Amin Jahanbakhshi
MGMarzieh Gomar
Marzieh Gomar
CICinzia Iotti
Cinzia Iotti
LGLucia Giaccherini
Lucia Giaccherini
PCPatrizia Ciammella
Patrizia Ciammella
Objectives: Common origins for brain metastases (BMs) are melanoma, lung, breast, and renal cell cancers. BMs account for a large share of morbidity and mortality caused by these cancers. The advent of new immunotherapeutic treatments has made a revolution in the treatment of cancer patients and particularly, as a new concept, if it is combined with radiotherapy, may lead to considerably longer survival. This systematic review and meta-analysis aimed to evaluate the survival rate and toxicities of such a combination in brain metastases. Methods: To perform a systematic review of the literature until January 2021 using electronic databases such as PubMed, Cochrane Library, and Embase; the Newcastle–Ottawa Scale was used to evaluate the quality of cohort studies. For data extraction, two reviewers extracted the data blindly and independently. Hazard ratio with 95% confidence interval (CI), fixed-effect model, and inverse-variance method was calculated. The meta-analysis has been evaluated with the statistical software Stata/MP v.16 (The fastest version of Stata). Results: In the first step, 494 studies were selected to review the abstracts, in the second step, the full texts of 86 studies were reviewed. Finally, 28 studies were selected consisting of 1465 patients. The addition of IT to RT in the treatment of brain metastasis from melanoma and non-small-cell lung carcinoma was associated with a 39% reduction in mortality rate and has prolonged overall survival, with an acceptable toxicity profile. The addition of IT to RT compared with RT alone has a hazard ratio of 0.39(95% CI 0.34–0.44). Conclusions: A combination of immuno/radiotherapy (IR) for the treatment of patients with BMs from melanoma and non-small-cell lung carcinoma has prolonged overall survival and reduced mortality rate, with acceptable toxicity. In terms of timing, RT seems to have the best effect on the result when performed before or simultaneously with immunotherapy.

28 September 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SBSalar Bijari
Salar Bijari
AJAmin Jahanbakhshi
Amin Jahanbakhshi
PHParham Hajishafiezahramini
Parham Hajishafiezahramini
PAParviz Abdolmaleki
Parviz Abdolmaleki
Due to different treatment strategies, it is extremely important to differentiate between glioblastoma multiforme (GBM) and brain metastases (MET). It often proves difficult to distinguish between GBM and MET using MRI due to their similar appearance on the imaging modalities. Surgical methods are still necessary for definitive diagnosis, despite the importance of magnetic resonance imaging in detecting, characterizing, and monitoring brain tumors. We introduced an accurate, convenient, and user‐friendly method to differentiate between GBM and MET through routine MRI sequence and radiomics analyses. We collected 91 patients from one institution, including 50 with GBM and 41 with MET, which were proven pathologically. The tumors separately were segmented on all MRI images (T1‐weighted imaging (T1WI), contrast‐enhanced T1‐weighted imaging (T1C), T2‐weighted imaging (T2WI), and fluid‐attenuated inversion recovery (FLAIR)) to form the volume of interest (VOI). Eight ML models and feature reduction strategies were evaluated using routine MRI sequences (T1W, T2W, T1‐CE, and FLAIR) in two methods with (second model) and without wavelet transform (first model) radiomics. The optimal model was selected based on each model’s accuracy, AUC‐roc, and F1‐score values. In this study, we have achieved the result of 0.98, 0.99, and 0.98 percent for accuracy, AUC‐roc, and F1‐score, respectively, which have yielded a better result than the first model. In most investigated models, there were significant improvements in the multidimensional wavelets model compared to the non‐multidimensional wavelets model. Multidimensional discrete wavelet transform can analyze hidden features of the MRI from a different perspective and generate accurate features which are highly correlated with the model accuracy.

3 January 2022 in Neurological Research
Verified
Journal Article
Closed access
ASAlireza Mohsenian Sisakht
Alireza Mohsenian Sisakht
NKNajme Karamzade-Ziarati
Najme Karamzade-Ziarati
AJAmin Jahanbakhshi
Amin Jahanbakhshi
KSKoorosh Shahpasand
Koorosh Shahpasand
SASamareh Aghababaei
Samareh Aghababaei
SZSelva Zamanzadeh
Selva Zamanzadeh
Traumatic brain injury (TBI) is the main cause of death and disability among young people. Following TBI, immune system activation and cytokine release induce kinase activity and hyperphosphorylation of tau protein, a structural molecule in axonal microtubules. The cis configuration of phosphorylated tau at Th231 is extremely neurotoxic and is having a prion nature, spreads to brain areas as well as CSF. We examined the cerebrospinal fluid (CSF) cis p-tau levels in 32 TBI patients and 5 non-TBI controls to find out the correlation with TBI severity. CSF samples were drained 5–7 days after TBI and subjected for ELISA analysis with anti cis p-tau and β-amyloid antibodies. We had no patients with mild TBI, two patients with moderate (6.2%), 23 patients with severe (71.9%), and 7 patients with critical TBI (21.9%). While mean CSF β-amyloid in TBI and control groups did not show a statistically significant difference, the mean CSF cis p-tau level was significantly higher in the TBI group than the control samples. Also, intergroup analysis demonstrated that CSF cis p-tau levels were statistically different according to the head injury severity. Although CSF cis p-tau increased in the TBI patients, β-amyloid did not show a significant difference between patients and controls. Also, we observed an obvious negative correlation between CSF cis p-tau levels and GCS scores. Therefore, future researches on suppression of cis P-tau production or removing previously produced cis P-tau could be a suitable approach in treating TBI in order to prevent tauopathies and future neurodegeneration.

20 October 2019 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
AJAmin Jahanbakhshi
Amin Jahanbakhshi
MAMaziar Azar
Maziar Azar
FKFarid Kazemi
Farid Kazemi
MJMaryam Jalessi
Maryam Jalessi
ICIran Chanideh
Iran Chanideh
EAElahe Amini
Elahe Amini